LEVOSALBUTAMOL MARKET

INTRODUCTION

A short-acting 2 adrenergic receptor agonist used to treat asthma and chronic obstructive pulmonary disease is levosalbutamol, often known as levalbuterol (COPD).

Levosalbutamol is thought to have a superior safety profile due to its more selective binding to 2 receptors (mainly in the lungs) versus 1 receptor, while evidence is unclear on the effectiveness of levosalbutamol over salbutamol or salbutamol-levosalbutamol combinations (primarily in the heart muscle).

The medication is the (R)-()-enantiomer of its salbutamol prototype. It is offered in various nations in generic forms made by drug manufacturers like Cipla, Teva, and Dey, among others.

Due to its bronchodilator effects, levosalbutamol is indicated for the treatment of asthma and COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease).

Similar to other bronchodilators, it shortens or reverses an acute "attack" of shortness of breath or trouble breathing by relaxing the smooth muscle in the bronchial tubes. It is not recommended as a treatment for chronic bronchial constriction, in contrast to several bronchodilators with a later onset of action. 

Levosalbutamol is typically well tolerated. Muscle cramps, gastrointestinal discomfort, and an increased heart rate are typical of moderate adverse effects (including heartburn and diarrhea).

Particular overdose symptoms include collapsing into a seizure, chest pain (possible heart attack precursor), a rapid, pounding heartbeat that may raise blood pressure (hypertension), irregular heartbeat that may paradoxically lower blood pressure (hypotension), nervousness and tremor, headache, nausea/vomiting, dizziness, dry mouth, and insomnia.

Rarer side effects could be an allergic reaction that could be hazardous. Itching, rash, or hives on the skin; angioedema of any area of the face or throat (which can cause voice hoarseness); paradoxical bronchospasm (shortness of breath and difficulty breathing); or swelling of the extremities are a few of these.

Adenylate cyclase is activated and the intracellular concentration of 3',5'-cyclic adenosine monophosphate increases when the 2 adrenergic receptors on airway smooth muscle are activated (cyclic AMP).

When cyclic AMP levels rise, protein kinase A is also activated. This lowers intracellular calcium concentrations and inhibits myosin phosphorylation, which causes muscles to relax.

LEVOSALBUTAMOL MARKET SIZE AND FORECAST

The Global LEVOSALBUTAMOL market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

LEVOSALBUTAMOL MARKET NEW PRODUCT LAUNCH

One of the top companies in the pharmaceutical sector, Anglo-French Drugs & Industries Limited, has announced the launch of new medicines in the AFD-PULMO-LS division. Levosalbutamol, Ambroxol, and Guaiphenesin are the three primary compounds found in cough syrup.

Excellent bronchodilator levosalbutamol safely and effectively opens the airways. A potent mucolytic, ambroxol dissolves phlegm, expels it from the lungs, and guards against the formation of new phlegm. medication that is mucoactive: guaiphenesin.

It improves bronchial secretion volume and lowers mucus viscosity, which helps to release mucus in the airways and facilitates expectoration, or coughing up mucus.

Additionally, AFD-PULMO-LS comes in a PET bottle that is unbreakable, has a measuring cap that is calibrated, has a great flavor (raspberry), and is sugar-free, making it suitable for diabetic people.

LEVOSALBUTAMOL MARKET COMPANY PROFILES

• Anglo-French Drugs & Industries Limited
• Wockhardt Limited
• Cipla
• Macleods Pharmaceuticals 
• Cross Berry

THIS LEVOSALBUTAMOL MARKET REPORT WILL ANSWER THE FOLLOWING QUESTIONS

1. How many LEVOSALBUTAMOL are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global LEVOSALBUTAMOL and key vendor selection criteria
3. Where is the LEVOSALBUTAMOL manufactured? What is the average margin per unit?
4. Market share of Global LEVOSALBUTAMOL market manufacturers and their upcoming products
5. The cost advantage for OEMs who manufacture Global LEVOSALBUTAMOL in-house
6. key predictions for the next 5 years in the Global LEVOSALBUTAMOL market
7. Average B-2-B LEVOSALBUTAMOL market price in all segments
8. Latest trends in the LEVOSALBUTAMOL market, by every market segment
9. The market size (both volume and value) of the LEVOSALBUTAMOL market in 2024-2030 and every year in between?
10. Production breakup of the LEVOSALBUTAMOL market, by suppliers and their OEM relationship